You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

M-M-R II ®

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Women of Child Bearing Potential Trial (R21/Matrix-M1, Saline and R21/Matrix-M1, Sterile isotonic (0.9%) normal saline)

Not yet recruiting
  • Healthy Women of Child Bearing Potential
  • R21/Matrix-M1
  • +2 more
  • (no location specified)
Oct 10, 2023

Lymphadenopathy Retroperitoneal, Stage II Testicular Seminoma Trial in Toronto (Robotic Retroperitoneal Lymph Node Dissection

Recruiting
  • Lymphadenopathy Retroperitoneal
  • Stage II Testicular Seminoma
  • Robotic Retroperitoneal Lymph Node Dissection (RPLND)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
May 16, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in Shanghai (Fluzoparib and Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Fluzoparib and Camrelizumab
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jun 4, 2022

Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
Oct 26, 2022

Oropharyngeal Cancer Trial in Canada (Radiation, Cisplatin)

Active, not recruiting
  • Oropharyngeal Cancer
  • Prince George, British Columbia, Canada
  • +13 more
Dec 12, 2022

Head and Neck Tumors Trial in Tainan, Taipei (SCB01A)

Terminated
  • Head and Neck Neoplasms
  • Tainan, Taiwan
  • +3 more
Jun 22, 2022

Prostate Carcinoma Trial in Canada (Low dose rate brachytherapy, High dose rate brachytherapy)

Recruiting
  • Prostate Carcinoma
  • Low dose rate brachytherapy
  • High dose rate brachytherapy
  • Ottawa, Ontario, Canada
  • +5 more
Feb 14, 2022

Cancer, Tumour, Surgery Trial in Canada, United States (Tranexamic acid (TXA), Normal saline)

Active, not recruiting
  • Cancer
  • +2 more
  • Tranexamic acid (TXA)
  • Normal saline
  • Rochester, Minnesota
  • +10 more
Oct 25, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Malignant Melanoma Trial in San Diego, Memphis, Houston (Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b)

Active, not recruiting
Has Results
  • Malignant Melanoma
  • Peginterferon alfa-2b
  • +2 more
  • San Diego, California
  • +2 more
Apr 1, 2022

Metastatic Cancer Trial in Canada (Stereotactic Ablative Radiotherapy (SABR), Standard of Care Treatment)

Active, not recruiting
  • Metastatic Cancer
  • Stereotactic Ablative Radiotherapy (SABR)
  • Standard of Care Treatment
  • Edmonton, Alberta, Canada
  • +6 more
Aug 22, 2022

Breast Cancer, DCIS Trial in Canada (APBI: 30 Gy, APBI: 27.5 Gy)

Active, not recruiting
  • Breast Cancer
  • DCIS
  • APBI: 30 Gy
  • APBI: 27.5 Gy
  • Barrie, Ontario, Canada
  • +9 more
Apr 4, 2022

COVID 19 Trial in Worldwide (MR or M-M-R II ® vaccine, Placebo)

Completed
  • COVID 19
  • MR or M-M-R II ® vaccine
  • Placebo
  • Saint Louis, Missouri
  • +16 more
Jan 25, 2022

Lung Cancer, Non Small Cell Lung Cancer, NSCLC Stage I Trial in Canada (Selective Targeted Sampling, Systematic Sampling)

Completed
  • Lung Cancer
  • +3 more
  • Selective Targeted Sampling
  • Systematic Sampling
  • Edmonton, Alberta, Canada
  • +6 more
Jul 25, 2022

Cutaneous Squamous Cell Carcinoma Trial in Italy (Cemiplimab)

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Bagno A Ripoli, Firenze, Italy
  • +6 more
Jul 27, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Advanced Rare Tumours Trial in Canada (Sunitinib, Temsirolimus)

Active, not recruiting
  • Advanced Rare Tumours
  • Calgary, Alberta, Canada
  • +16 more
Mar 17, 2022

Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Malaria Trial (R21/Matrix-M™)

Recruiting
  • Malaria
  • R21/Matrix-M™
  • Entebbe, Uganda
    MRC/UVRI & LSHTM Uganda Research Unit
Jan 13, 2023